-
Uncategorized3 weeks ago
Molecular Pathways Driving Autoantibody Production Following SARS-CoV-2 Infection Identified
When the immune system encounters a virus, it produces antibodies designed to recognize and eliminate the invader. But in some people infected with SARS-CoV-2 the immune...
-
Capital, M&A & Industry Strategy3 weeks ago
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The...
-
Uncategorized3 weeks agoModerna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of...
-
Uncategorized3 weeks ago
‘Worse than expected’ Wainua data muddies water for TTR silencers
AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined...
-
Uncategorized3 weeks ago
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.
-
AI, Machine Learning & Computational Biology3 weeks agoAstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
-
Uncategorized3 weeks ago
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder...
-
Uncategorized3 weeks ago
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.
-
Uncategorized3 weeks ago
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
-
Uncategorized3 weeks ago
Multispecifics are transforming the CDMO development architecture
Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
